-5%
Erythropoietin is used in adults and in children to treat:
- Anemia (low RBC in blood) caused due to chronic kidney disease, chemotherapy, anti-viral therapy (Ex. zidovudine), blood donation, or any bone marrow disorders/cancers (such as myelodysplastic syndromes)
- Prevent or manage anemia in patients undergoing any major bone surgery (such as hip or knee replacement operations)
- Reduce the need for blood transfusion in cancer patients and patients undergoing bone surgery or chemotherapy
Epoetin 2000 IU Injection contains Epoetin Alfa, which is categorized as an Erythropoiesis-stimulating agent. It is primarily used to treat anemia resulting from various conditions such as chronic kidney disease, chemotherapy, bone marrow disorders, or cancers. Additionally, it can be utilized to prevent or manage anemia in patients undergoing major bone surgeries. This medication may reduce the need for blood transfusions in cancer patients or those undergoing bone surgery or chemotherapy.
- Epoetin 2000 IU Injection is suitable for both adults and children.
- During treatment, your doctor will regularly monitor your blood pressure and iron levels to adjust the dosage and minimize the risk of adverse effects.
- Inform your doctor about any liver, kidney, or heart problems before receiving an Epoetin 2000 IU Injection.
- Disclose any history of high blood pressure, diabetes, obesity, breast cancer, head and neck cancer, seizures, blood clots, dialysis, or surgery.
- Epoetin 2000 IU Injection is not recommended for patients with recent heart attacks or strokes, severe uncontrollable high blood pressure, or pure red aplastic anemia.
- Inform your doctor if you are pregnant or breastfeeding before receiving Epoetin 2000 IU Injection as a precautionary measure.
Epoetin 2000 IU Injection is a valuable treatment option for managing anemia associated with various medical conditions. However, it is crucial to inform your doctor about any pre-existing medical conditions and closely monitor for potential side effects during treatment.
